Chardan Capital Reiterates Neutral on ProQR Therapeutics, Maintains $2 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a Neutral rating on ProQR Therapeutics (NASDAQ:PRQR) and maintained a $2 price target.
August 04, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ProQR Therapeutics' stock rating has been reiterated as Neutral by Chardan Capital, with a maintained price target of $2.
The reiteration of a Neutral rating indicates that the analyst believes the stock will perform in line with the market average. This is neither a positive nor a negative signal for investors. The maintained price target of $2 suggests that the analyst does not foresee significant price movement in the near term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100